Nurix Therapeutics EBIT

Nurix Therapeutics (NRIX) currently reports a EBIT of $300M as of August 2026. That compares with $-260M in the prior-year period — up 215.5% year over year. That is below the Healthcare sector average of $2T. Use the charts on this page to explore Nurix Therapeutics's EBIT history and peer comparisons.

Nurix Therapeutics's EBIT increased from $-260M to $300M — a 215.5% year-over-year increase (period ending August 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Nurix Therapeutics's EBIT of $300M is lower than the Healthcare sector average of $2T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Nurix Therapeutics reported $300M in EBIT as of August 2026. That compares with $-260M in the prior-year period — up 215.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $300M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $2T. From there, open related valuation or income-statement pages for Nurix Therapeutics, and consider following NRIX for alerts when major investors trade the stock.